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 ABSTRACT 
Dengue is a re-emerging global public health threat that over one-third of the world’s 
current population stands at risk of developing.  Persistent upticks in climate warming, 
population growth and global transportation have the potential to spread the four dengue virus 
(DENV) serotypes to new geographical areas, thereby increasing the number of at-risk 
individuals. Annually 50 to 100 million dengue cases develop worldwide; approximately five 
hundred thousand of these cases degenerate into severe disease.  In some instances, regions 
lacking the means to provide supportive therapy have experienced 40 percent case-fatality rates. 
The economic and global impacts of dengue remains unchallenged due to inadequate control 
measures and the absence of licensed vaccines.  A more thorough understanding of DENV 
pathogenesis would open the door to designing the effective vaccine and antiviral drug 
candidates essential to the global health community’s efforts to control dengue. This thesis 
focuses on understanding a recently observed characteristic of DENV pathogenesis: four to 
seven days after disease onset, peripheral plasmablasts undergo a massive expansion.  Relative to 
other heavily studied cell types, very little is known about the role plasmablasts play in the 
overall model of DENV pathogenesis.  At the start of this project, it was unknown if this robust 
plasmablast response to DENV originated from the DENV specific memory B-cell subset or if it 
was driven by naïve B-cells.  To facilitate investigation of the events relating to DENV-induced 
B-cell activation, peripheral blood mononuclear cells (PBMCs) were collected from healthy 
individuals with previous DENV exposures.  Using an in vitro model, I showed that DENV was 
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able to drive differentiation of DENV specific memory B-cells into DENV specific IgG secreting 
plasmablasts.  After observing that DENV could drive a plasmablast response, I also 
demonstrated that monocytes, the primary target cells, played an important role in this 
plasmablast development. This work leads to the important conclusion that DENV is able to 
drive the differentiation of DENV specific memory B-cells into IgG secreting plasmablasts with 
the help of monocytes.  However, it is unlikely that the secondary response mounted by this 
memory subset will be sufficient to produce the high percentage of plasmablasts seen in acute 
patients. These research findings are important in the ongoing effort to identify the early events 
essential for driving the robust plasmablast response observed during DENV infections. 
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1.0 INTRODUCTION 
Dengue is the most important mosquito-borne viral infection occurring in tropical and 
sub-tropical regions.  This disease has emerged as an alarming public health threat, especially in 
developing countries.  An estimated 50 to 100 million dengue virus (DENV) infections occur 
annually [1], with over one hundred countries endemic with at least one DENV serotype.  The 
number of individuals at risk for contracting DENV infections may increase in upcoming 
decades as the habitat range of its vector, the Aedes species mosquito, continues to spread 
geographically [2, 3]. 
There are currently four genetically distinct DENV serotypes (1-4) scattered around the 
world.  During the past few decades, many countries that were once endemic with a single 
DENV serotype now have multiple circulating serotypes.  Overall, the reported incidence of 
severe dengue has increased over 500-fold since the 1950s [4, 5].  It is suspected that this higher 
prevalence of severe infections is linked to the increase in heterotypic DENV infections in a 
given region, but this remains an outstanding question [6-9]. 
Other than supportive treatments, there are currently no licensed vaccines, anti-virals or 
therapeutics available to prevent or treat severe infections.  Despite the decades devoted to 
unraveling the factors which drive the immunopathogenesis of DENV infections, the dynamic 
host and viral factors that contribute to the development of severe disease have yet to be fully 
elucidated [10].  Therefore, the pathogenesis of DENV infections requires further research. 
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1.1 GLOBAL IMPACT OF DENGUE 
1.1.1 Disease Burden 
Dengue threatens an estimated 2.5 billion people -or about one-third of the world’s 
population- with significant medical, social and economic burden.  In 2010, the World Health 
Organization (WHO) reported the overall severe disease burden to be approximately five 
hundred thousand cases annually with a 1-5 percent case-fatality rate.  In the absence of 
supportive therapy, this case-fatality rate rose up to 40 percent in some regions [9, 11]. 
However, many experts believe that these disease burden estimates are highly conservative.  A 
recent mapping exercise conducted by the Spatial Ecology and Epidemiology Group at Oxford 
suggests that the actual burden of dengue is about three times higher than current WHO 
estimates [12]. 
1.1.2 Emergence 
Dengue has accompanied human society throughout history.  The earliest records of 
dengue-like symptoms were documented during the Chin Dynasty, 265-420 A.D [13]. 
Throughout the 18
th
 and 19
th
 centuries, dengue was primarily observed in parts of Asia and the
Americas with a major epidemic in Philadelphia in the 1780s [14]. However, these localized 
dengue outbreaks differed from the global disease present today because expansion of mosquito 
vectors and infected human hosts occurred at a much slower rate. During World War II, 
movement of viremic troops and refugees across the globe facilitated the spread of dengue to 
new areas [15].  Combined with post war population growth, rapid urbanization and poor vector 
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control, this heightened trans-continental travel led to the establishment of dengue hyper-
endemic areas in Asia and the Pacific [16].   Dengue’s reach continues to expand dramatically.  
Many countries in Asia, Africa and the Americas now show all four dengue serotypes in 
circulation when during World War II and up to twenty years ago they evidenced only one or 
two serotypes [17].  
1.2 DENGUE VIRUS 
1.2.1 Genome/Structure 
DENV is part of the genus flavivirus from the family Flaviviridae.   The Flaviviridae 
family includes other relevant, serologically related viruses such as West Nile virus, yellow fever 
virus, and Japanese encephalitis virus.  The genome is an ~11 kb single stranded positive sense 
RNA genome that has one open reading frame which is translated into a single polyprotein. This 
genome encodes three structural proteins: the nucleocapsid (C), the membrane associated protein 
(M), and the E protein.  It also encodes seven non-structure proteins that are essential for viral 
replication: NS1, NS2A, NS2B, NS3, NS4A, NS4B, and NS5 [18-20].  Electron micrographs 
show the virion to measure 50 nm as an immature particle and 60 nm as a mature particle [21]. 
Inside the virion, viral C proteins encasing the viral genome form the nueclocapsid which is 
surrounded  by a host-derived lipid bilayer with an icosahedral scaffold consisting of 180 copies 
of E protein monomers.  The E protein plays an essential role in facilitating the virion’s 
attachment and fusion with susceptible cells.  All four serotypes share similar epitopes on the E 
protein that lead to extensive cross-reactivity [19, 22-24]. 
4 
1.2.2 Transmission and Life Cycle 
The Aedes aegypti mosquito is the principal DENV vector; Aedes albopictus is the 
secondary vector.  The Aedes mosquito species are found in urban areas.  They prefer to lay their 
eggs in standing water near or under houses.  Once a mosquito feeds on an infected host and 
contracts DENV, it is infected for life [21]. DENV is transmitted to the human host when an 
infected mosquito inserts its proboscis into the upper dermis layers while searching for the 
capillaries to take a blood meal. The virus enters the human host through the mosquito saliva that 
is injected during feeding [21, 25, 26].  Disease onset occurs typically four to six days after the 
virus is introduced into the skin [27]. 
Once the transmitted virus makes contact with susceptible cells, it enters the cells through 
receptor-mediated endocytosis using receptors such as dendritic-specific intercellular adhesion 
molecule 3(ICAM-3)-grabbing nonintegrin (DC-SIGN) [19].  In vitro, it has been observed that 
the virus primarily targets monocytes/macrophages for DENV infection, as well as Langerhan 
cells and dermal dendritic cells.  However, the precise in vivo targets are still not known [28]. 
After entering the cell, acidification of the endosome triggers a conformational change which 
causes the projection of fusion peptides located on the E protein to facilitate the fusion of the 
virus membrane with the host membrane [24].  This opens the viral particle, releasing the viral 
genome into the cytoplasm.  In the cytoplasm, the viral RNA dissociates from the nucleocapsid 
and associates with endoplasmic reticulum (ER) derived-membranes.  Replication of the viral 
genome and assembly of the virion is initiated in the ER.  Translation of the genome involves the 
production of a single polyprotein that is cleaved at specific sites by both host proteases and the 
viral NS3/NS2B protease. The immature particles travel through the Golgi and are released from 
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the cell by exocytosis. Mature particles are produced when the endoprotease furin cleaves the 
pre-membrane protein (prM) to produce virus associated M, an infectious particle [19, 29, 30]. 
1.3 CLINICAL CLASSIFICATIONS AND MANIFESTATIONS 
1.3.1 Changes in Clinical Classifications 
Over the past decades, it became apparent that the previous system for classifying DENV 
infections was no longer suitable for standardizing treatment and clinical practice. This system, 
based on the original 1975 guidelines, proved too complicated for medical professionals to use in 
the proper treatment and classification of dengue patients.  In an effort to ease the triage process, 
the WHO revised this classification system in 2009 to account for the variable disease 
manifestations recorded across multiple geographical regions [31-33]. 
In the past, dengue outcomes were categorized as dengue fever (DF), and dengue 
hemorrhagic fever (DHF) grades I-IV with IV representing dengue shock syndrome (DSS). The 
2009 system removes this grading system and only considers three different categories of 
disease: dengue, dengue with warning signs and severe dengue [33].  This new system is hoped 
to ease management of clinical patients and allow for greater sensitivity to a severe dengue 
diagnoses [31, 32, 34, 35]. However, some researchers opine that categorizing dengue as a 
spectrum of disease outcomes will impede the study of DENV pathogenesis. They argue that 
understanding dengue as a distinct set of disease outcomes is essential to elucidating the factors 
driving severe disease development as different immune mechanisms may be involved in 
different clinical outcomes [32, 33].  Advocates of the new system cite the lack of progress in 
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understanding DENV pathogenesis under the old system as justification that the classification 
changes will not have any negative effects on research [32]. 
1.3.2 Clinical Manifestations 
The disease outcomes of DENV infections range from asymptomatic infections to severe, 
life-threatening infections. Based on the WHO/SEARO 2011 Comprehensive Guidelines for 
Prevention and Control of Dengue and DHF, which use the older classification system, cases can 
be categorized as undifferentiated febrile illness (UF), DF, DHF, and DSS.  UF is commonly 
seen in primary dengue.  Confirmation of DENV infections in UF cases relies on serological 
testing, as healthcare professionals cannot diagnose these patients based on clinical observation 
alone. DF, an acute febrile illness also called break-bone fever, is associated with severe 
headaches, joint pain, and occasionally haemorrhaging. DHF manifests similar symptoms to DF 
during the febrile phrase.  The development of significant plasma leakage and abnormal 
haemostasis distinguishes DHF from DF.  Warning signs such as persistent vomiting, abdominal 
pain, lethargy or restlessness can precede severe disease outcomes. DSS occurs when the plasma 
leakage observed during DHF becomes so severe that it causes the patient to go into shock [27, 
36, 37]. 
Implementation of the new classification system is hoped to allow for the distinct 
classification of patients. The category of dengue is assigned to patients who recover after 
defervesecence. Patients classified as dengue with warning signs suffer from symptoms such as 
persistent vomiting, abdominal pain, lethargy, etc. Severe dengue indicates patients who develop 
severe plasma leakage or severe bleeding. This new system has yet to be practically shown as a 
relevant alternative to the previous system. To optimize this dengue classification system, 
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researchers may need to implement further modifications as well as incorporate elements from 
the previous naming system [34]. 
1.4 PRINCIPAL RISK FACTOR: SECONDARY INFECTIONS 
In the late 1970s Scott Halstead proposed the “sequential infection hypothesis”. This 
hypothesis was the first to suggest that pre-existing immunity to any DENV serotype may be 
linked to the development of severe disease [6]. To investigate his theory, Halstead studied a 
group of patients admitted to the Children’s Hospital in Bangkok, Thailand. Forty percent of the 
523 children hospitalized with DHF had symptoms of shock. When analyzing the serum of these 
children, Halstead found a correlation between antibodies to a secondary DENV serotype and the 
development of shock and [38].  In the 1980s, Donald Burke and several others conducted a 
follow-up study in Bangkok, Thailand.  They also found evidence indicating that an infection 
with a second DENV serotype was a principal risk factor for developing severe disease. Fifty 
percent of the children recruited into the study had already become infected with at least one 
serotype. When they actively surveyed these children for seven months, 69 percent of the 
children who developed secondary symptomatic infections were described as DHF. In this study, 
they observed a higher prevalence of DHF infections in children with pre-existing immunity 
compared to children without said immunity [6].  This study was the first comprehensive study 
to link the presence of pre-existing immunity to DENV with the severity of disease manifestation 
observed [6, 8, 38, 39].  
Another important study occurred in Cuba during the 1970s and 1980s. For the first time, 
investigators were able to directly study the effects of a second DENV serotype entering into an 
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already exposed population [40, 41]. Between 1977 and 1979, 50 percent of the Cuban 
population was infected with DENV-1. Two years later, DENV-2 was introduced into the 
population, producing the first major DHF/DSS epidemic in Cuban history [41]. DHF/DSS was 
observed in the adult population for the first time, and 98 percent of the DHF/DSS adult cases 
were found to have pre-existing immunity to the previously endemic DENV serotype. Among 
the 124 child cases of DHF, 122 of these children with DHF/DSS had pre-existing immunity to 
DENV. There were no hospital cases or fatalities in children who were born after the DENV-1 
epidemic. The observations made in this study were consistent with other studies of DHF in 
children with secondary exposures and with Halstead’s hypothesis of sequential infection [42]. 
1.5 CAUSATION OF SEVERE DENV INFECTIONS 
1.5.1 Antibody Dependent Enhancement 
The current central dogma explaining the causation of severe disease development is 
antibody dependent enhancement (ADE) [38, 43, 44].  ADE is based on the hypothesis that in an 
environment of sub-neutralizing antibodies, enhanced infection of monocytes and other 
susceptible cells with Fc receptors is promoted through the uptake of sub-neutralized virus-
antibody complexes. This mechanism of enhanced infection due to ADE has been previously 
observed in vitro with other viruses [45-47]. It is proposed that when an individual with pre-
existing immunity to DENV is infected with a different serotype the antibody response produced 
is sub-neutralizing and specific for the original infecting serotype. These sub-neutralizing 
antibodies are presumed to bind to the heterotypic DENV due to cross-reactivity and enhance the 
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infection of monocytes and macrophages. These increased levels of infected monocytes leads to 
higher levels of viremia, which is linked to the development of severe disease outcomes [48]. 
However, despite multiple clinical studies, direct evidence in support of ADE and its role 
in human infections has yet to be confirmed [43, 46]. Mice models provide the main in vivo 
model to study ADE. These studies have shown that antibodies can either neutralize or enhance 
DENV infections depending on their concentrations [43]. In humans, evidence in support of 
ADE come from epidemiological studies that report a high incidence of severe infections among 
infants, aged six to nine months, with waning passive maternal immunity received from dengue 
immune mothers [38, 49]. In addition, a study conducted in Thailand observing the ADE 
qualities of serum collected pre-infection with a second dengue serotype yielded evidence that 
suggested in vitro ADE activity was a good predictor for severe disease outcome [50].  Despite 
in vitro and clinical observations, the evidence in support of ADE remains circumstantial. Severe 
dengue infections are also observed in individuals with primary infections, so researchers have 
concluded that other factors must play a role in driving severe disease development. [46]. 
1.5.2 Other cellular factors 
The role of cellular immunity during severe dengue infections has been closely studied, 
especially since increases in soluble factors such as interleukin-2 (IL-2), interferon- , 
tumor necrosis factor-alpha (TNF-, macrophage inflammatory protein-1beta (MIP-1, and 
soluble CD8 in patient serum is linked to severe disease outcomes [51]. When monocytes 
become infected, they secrete TNF-, interleukin-6 (IL-6), and IFN- that lead to the 
reactivation of DENV specific CD4
+
 memory T-cells.  This T-cell activation also leads to
increased cytokine expression [52]. Some groups predict that the reactivation of memory T-cells 
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specific for the original infecting serotypes results in a skewed memory response consisting of 
low avidity cross-reactive T-cells, also known as original antigenic sin. This skewed response, 
based on in vitro studies, is proposed to alter the kinetics and the profile of cytokine secretion 
leading to an increase in IFN-, TNF- and MIP-1 [51]. 
Until recently, most pathogenesis studies focused on factors related to humoral or cellular 
immunity such as the antibody profiles present during infection, or the skewed T-cells responses 
driving the cytokine storms, but few studies focused on the roles which other cell types might 
play. Outside of the dynamic cross-reactive antibody profiles produced by the B-cells, few 
studies have delved into the other possible roles of this cell type. Current observations suggest 
that researching B-cells may shed further light on the factors driving dengue disease progression. 
1.6 HUMORAL IMMUNITY 
1.6.1 B-cells 
B-cells, historically called bone-marrow derived lymphocytes, are the lymphocyte 
population responsible for secreting antibodies against specific antigen epitopes leading to 
neutralization and clearance. They are primarily identified by the expression of CD19, as all B-
cell lineage cells express this surface molecule [53]. CD20 is also a surface marker for 
identifying mature B-cells. However, this marker is down regulated once committed to 
developing into plasmablasts, a professional antibody secreting cell described in later sections 
[53, 54]. B-cells are essential for long-term humoral memory and protection as antibody titers 
after natural or vaccination-induced immunity is considered a biomarker for a ‘correlate of 
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protection’ [55, 56]. Intimate knowledge of this cell type constitutes an important step towards 
unraveling the role they may play in immunopathogenesis as well as providing specific long-
term protection against pathogens [57]. 
Ever since their discovery and characterization in the mid-1960s, B-cells have been 
divided into multiple subsets based on their unique combinations of surface markers and the 
different roles each distinct phenotype plays [53]. 
1.6.1.1 Development of Memory B-cells, Plasmablasts and Plasma Cells 
The activation of naïve circulating B-cells after antigen challenge, which leads to their 
differentiation into acute plasmablasts or antibody secreting cells (ASCs), is relatively well-
defined [57]. Upon recognizing the challenging antigen, activated naïve B-cells migrate to the 
secondary lymph node organs and home to the T-cell-B-cell border where they interact with 
follicular T-cells and their cognate T-helper cell [58]. This interaction pushes the naïve B-cell to 
differentiate into first responder low-affinity acute IgM ASCs or to become founder cells for 
germinal centers (GC) [56, 59]. Somatic hypermutation (SHM) and class switching occurs in the 
GC to select the B-cell clones with the highest affinity to the invading antigen [56]. After 
founder B-cells form a GC and undergo SHM, they begin the process of either differentiating 
into acute plasmablasts, memory B-cells or long-lived plasma cells. 
Plasmablasts are an intermediate subset between an activated B-cell and a plasma cell. 
Plasmablasts and plasma cells are similar in that they both are professional antibody secreting 
cells that down-regulate CD20 and up-regulate CD38 and CD27.  These two subsets differ in that 
plasmablasts still undergo cell cycling and proliferation and have not started to express CD138, 
while plasma cells express CD138, have extremely low CD19 expression and are terminally 
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differentiated [54, 60]. If the plasmablasts do not directly differentiate into plasma cells and 
survive in the lymph node, they will exit into circulation and survive only a short time during the 
infection to secrete high amounts of antigen specific antibodies [60]. It is still not clear if these 
acute plasmablasts are able to home to survival niches such as the bone marrow and differentiate 
into long-lived plasma cells [54, 60]. 
Memory B cells represent the immunological memory branch of the immune system 
because they are the main mediators of the secondary responses to infection. This subset is 
distinguishable from naive B-cell subsets based on their expression phenotype 
CD19
+
CD27
+
CD38
-
, their longevity and their ability to produce high affinity antibodies [54, 61].
Memory B-cells have high affinity B-cell receptors (BCR) that are extremely sensitive to their 
cognate pathogen. After sensing their antigen, memory B-cells will rapidly differentiate into IgG 
secreting plasmablasts because their signal and cytokine requirement is much lower compared to 
a naïve B-cell [57, 62, 63]. However, the particular signals necessary to drive the secondary 
response facilitated by re-activated memory B-cells remain poorly understood. Some studies 
identify cell populations such as T-cells or monocytes as important while others suggest that 
activation through the BCR by the antigen alone is sufficient to drive the classic anamnestic 
response [62, 64]. After the antigen is cleared, the memory B-cells remain quiescent in the 
periphery; how this subset is maintained for decades in the absence of antigen remains unknown. 
Throughout an individual’s lifetime, the memory B-cells generated by primary and secondary 
exposures persist for life-providing protective immunity against reinfection [56, 57].  One caveat 
is that any defect or alteration in the signals required for regulating this process can promote 
pathogenic outcomes, either through a lack or overabundance of antibodies due to an unregulated 
immune response. 
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1.6.2 Role of T-cells and Monocytes in Plasmablast Development 
The particular microenvironment where the activated and developing B-cell resides 
regulates their phenotypic outcome. The cytokine profile is particularly important in modulating 
the transcription factors that influence the up or down regulation of certain surface molecules.  In 
the 80s and 90s, a myriad of cytokines such as IL-6, interleukin-10 (IL-10), a proliferating-
inducing ligand (APRIL) and B-cell activating factor (BAFF) were discovered and found to 
promote survival, proliferation, isotype switching and differentiation of B-cells [59, 60]. The 
particular combinations of these cytokines and others are responsible for regulating the 
development of the different subtypes; however, researchers still have not pinpointed the exact 
signals required to drive the differentiation of a memory B cell versus a plasmablast [59]. 
It is known through in vitro studies that T-cells are important for this process as IL-2 
enhances proliferation upon CD40L interactions, which is provided by direct T-cell interactions 
[59]. However, the role of T-cell help in the formation of plasmablasts is still not clear especially 
in secondary verses primary infections [54]. IFN- has also been identified as an important 
cytokine to push the differentiation of B-cells into plasmablasts in an IL-6 environment. IL-6 is 
predominantly secreted by monocytes [59].  Previous publications provide evidence that the 
microenvironment where plasmablasts mature are rich in IL-6 and APRIL, which are secreted by 
monocytes/macrophages and dendritic cells [58, 60]. 
As mentioned above, plasmablasts enter the peripheral blood after their formation in the 
GC, retaining their ability to both proliferate and secrete high amounts of antigen specific 
antibodies. Multiple studies have noted that the plasmablast’s kinetics are fairly consistent. 
Regardless of vaccine or antigen based activation, plasmablasts peak in the periphery 6-7 days 
post primary contact with the antigen [54, 65, 66]. This response lasts as long as viral antigen is 
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present in the system, but afterwards the number of plasmablasts rapidly drop off as the infection 
clears [54].   
1.6.3 Humoral Immunity and DENV Infections 
In the context of DENV infections, very little is known about the role plasmablasts play 
because most studies merely focus on the cross-reactive or the neutralizing profile of the 
antibodies produced. Recent studies delving into the role these cells may play have found that 
individuals infected with DENV have a very robust plasmablast response that peaks four to 
seven days after the onset of symptoms [54, 67-69]. One study completed in Thailand using a 
cohort of adults and children hospitalized with dengue observed that six to seven days post onset 
of symptoms there was a massive plasmablast response. The kinetics of this response occurred 
within the expected timeframe, but the extremely high presence of plasmablasts observed was 
distinctive. On average, the peak plasmablast response was 47 percent of all peripheral CD19
+
 B-
cells with some individuals reaching 80 percent [68]. During other acute infections or 
vaccination boosters, the peak in plasmablasts usually occurs six to seven days post exposure, 
but only around 5 to 20 percent of the total CD19 population develop the plasmablast phenotype 
[66]. In subjects receiving the primary yellow fever virus vaccine or the influenza vaccine, only 
2 to 3 percent of their CD19
+
 cells were identified as plasmablasts [68]. In addition to this, at
least 70 percent of the plasmablasts produced were dengue specific IgG secreting cells indicating 
this is a targeted rather than a massive non-specific response [68]. There was no observable 
difference between the plasmablast responses mounted in individuals infected with different 
dengue serotypes. 
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Our lab has recently published data observing a similar pattern using a cohort of 
individuals from Brazil. We found that among the individuals who were suffering from severe 
dengue infections, there was a massive plasmablast response peaking four to seven days after the 
onset of symptoms that averaged 47 percent and rose as high as 87 percent of the peripheral 
CD19
+
 B-cell population. Unlike the previous study, there were enough individuals with primary
infections to compare the plasmablast responses between severe secondary and primary DENV 
infections. We found that there was a significant difference in the number of plasmablasts 
between severe primary and secondary infections. In this study, we also found that over 70 
percent of these plasmablasts were specific for DENV. The antibodies produced by these 
plasmablasts were three times greater in their reactivity against the current infecting DENV 
serotype, not the previous infecting serotype [67].  
It is not clear how this very potent DENV specific plasmablast response fits into the 
current model of DENV pathogenesis, but it is believed that this response plays an important 
role. Some speculate that the reactivation of DENV specific memory B-cells early in infection 
facilitates the production of antibodies which lower virema.  In turn, this lowers the overall viral 
load to decrease the chances of severe disease progression [69]. However, no studies have 
conclusively investigated the profiles of these antibodies produced during secondary infections. 
It is also possible that a large reactivation of memory B-cells specific to the previous infecting 
serotypes may drive ADE, causing a high viral load and severe infection. The founding 
population of the plasmablasts that drive this robust plasmablast response remains unknown. It is 
possible that a skewed memory B-cell response could drive this potent response and influence 
the overall humoral response to the heterotypic DENV infection. 
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Identifying the origins of this plasmablast response and its impact on the disease may 
provide new opportunities to design more targeted vaccine candidates. When developing an 
effective vaccine, especially for DENV, it is essential that the vaccine protectively targets and 
‘teaches’ the immune system how to properly respond to the infection when re-challenged. 
Therefore, more research is required to elucidate whether or not this potent plasmablast response 
is the result of an immune response skewed towards protection or pathogenesis. 
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2.0 PROJECT AIMS 
Before moving towards future studies to link this potent plasmablast response to disease 
outcomes, I first wanted to investigate the possible origins of this plasmablast response. To 
understand if these plasmablasts originated from a skewed memory B cell response or a robust 
activated naïve B-cell response, I first decided to focus on the reactivation potential of DENV 
specific memory B-cells. For this study, my primary goal was to examine the in vitro 
requirements for re-activating DENV specific memory B cells and driving them to differentiate 
into IgG secreting DENV specific plasmablasts. 
AIM 1: Investigate the ability of DENV to stimulate the differentiation of DENV specific 
memory B-cells into plasmablasts. Hypothesis: DENV is able to directly stimulate DENV 
specific memory B-cells and drive them to differentiate into DENV specific plasmablasts. 
Approach: I will stimulate PBMCs from individuals who had previous DENV infections with 
DENV before culturing for seven days. Then I will assess the phenotype of the ASCs by flow 
cytometry and their specificity by ELISPOT to evaluate the ability of DENV to drive the 
differentiation of plasmablasts in culture.  
AIM 2: Determine the role of monocytes in promoting the in vitro expansion of 
plasmablasts in response to DENV stimulation. Hypothesis:  Other cell populations such as 
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monocytes may play a role in assisting the differentiation of DENV specific memory B-cells into 
plasmablasts. Approach: Using magnetic beads, CD14
+
 monocytes will be depleted from the
PBMC samples before stimulating with DENV and culturing for seven days. Flow cytometry 
analysis will be used to observe if this causes a decrease in the frequency of plasmablasts 
produced in culture. After forty-eight hours, I will look for the presence of infected monocytes 
by utilizing fluorescently labeled 2H2 antibodies to probe for the presence of intracellular virus. 
3.0  MATERIALS AND METHODS 
Isolation of PBMCs from blood donors  
The University of Pittsburgh IRB approved blood collection from healthy donors with 
and without pre-immunity for dengue, and these donors gave their informed consent.  Three of 
the six donors used in this study had been exposed to dengue >10 years prior to the blood draw.  
ELISA confirmed the presence of dengue specific antibodies in their serum. The three remaining 
donors self-reported that they had had no known exposure to the dengue virus or history of 
potential dengue-like disease. ELISA showed a lack of dengue specific antibodies and 
Confirmed their dengue naïve status. Venous blood was collected using heparin or acid citrate 
dextrose tubes once or multiple times during a 9 month period depending on the donor. PBMCs 
were isolated using gradient centrifugation over Ficoll-Hypaque. Any contaminating red blood 
cells were lysed by ACK treatment for 10 minutes RT. The PBMCs were then washed twice in 
MACs Buffer (PBS, 0.1 EDTA, 5% BSA, HEPES) and re-suspended in 10% dimethylsulfoxide 
(DMSO)/fetal bovine serum for cryopreservation at a concentration of 1x107 cells/ mL per vial.  
Virus-capture ELISA 
Determination of the presence of DENV specific antibodies in the serum samples 
collected from the donors was performed by virus-capture ELISA. The ELISA plates were 
coated using 1ug/well of 4G2 antibody (a pan DENV envelop antibody, produced and kindly 
gifted by Eduardo N, Center for Vaccine Research, University of Pittsburgh PA USA) in sodium 
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bicarbonate carbon buffer pH 7.4. 50 uL/well of this mixture was then incubated overnight at 
4oC. The 4G2 was washed off with wash buffer (PBS, 0.1% Tween-20) then incubated at 37oC 
for an hour in blocking buffer (5% milk in PBS). Afterwards, the plate was washed 3x with wash 
buffer before the addition of an equalized DV-2 and DV-3 virus supernatants in C6/36 growing 
media (DMEM, 2% FBS, 1% phosphate broth) (gifted by Eduardo N.). The plate was incubated 
for 2 hours at 37oC and then washed 5 times with wash buffer. Serum samples from each donor 
were diluted at 1:100 in 1% milk PBS before being added to each well and incubated overnight 
at 4oC. The plate was then washed 2x before the addition of 1:10000 anti-IgG antibody (Jackson) 
in 1% milk PBS and incubated at 37oC for 1 hour. The plate was washed 3x in wash buffer and 
1:10000 of anti-IgG HRP in 1% milk (Jackson) was added to the plate. After the plate was 
incubated for an hour at 37oC, the plate was washed 3x with wash buffer, and 50 uL/well of 
TMB was added for 20 minutes. After 20 minutes the reaction was stopped by adding 25 uL/well 
of 2N HCl. The OD was read and then analyzed using Graphpad Prism 6.  
Stimulation of cryopreserved PBMCs with virus 
The cryopreserved PBMCs were quick thawed in a 37oC warm water bath and washed in 
R-10 (RPMI-1640, 10% FBS, 1% Pen/Strep, 1% L-glut, 1% Non-essential amino acids, 1% 
sodium pyruvate, 1% HEPES) culture medium. They were rested in 10 mL of medium for 2 
hours prior to stimulation with DENV in 5% CO2 at 37oC. The cells were stimulated in 15 mL 
conicals using virus re-suspension medium alone (20nm HEPES, 3% FBS, DMEM) or with an 
MOI 3 of DENV 2 or 3, influenza virus (H7N9 a gift from the Ted Ross, previously Center for 
Vaccine Research, University of Pittsburgh, PA USA) or 240 nm of SIV251 capsid protein (a gift 
from Jeff Listone). After re-suspending 5x105 cells/275 uL in a mixture of virus and virus re-
suspension media or virus re-suspension media alone, the cells were incubated in 5% CO2 at 
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37oC for two hours. Then the virus was washed off the cells by filling the 15 mL conicals with 
R-10 medium and spinning the cells down. The cells were re-suspended in R-10 medium at a 
concentration of 100, 000 cells/100 uL. As a positive control some of the cells not stimulated 
with virus were stimulated with a mixture of Phytolacca Americana pokeweed mitogen 
(1/100,000 dilution), Staphylococcus Aureus Cowan (SAC) (Sigma) (1/10,000 dilution) and 
6ug/mL of CpG 2006 (Invitrogen). They were cultured ~171, 000 cells/well in a 96 round-well 
culture plate in 5% CO2 for 7 days. 
Detection of plasmablast by flow cytometry 
After the PBMCs were either thawed or cultured for 7 days, they were incubated at 
various concentrations in the master mix of different combinations of the fluorochrome-labeled 
Ab from BD science. The main antibody panel used was CD19 (clone HIB19 PE-Cy7), CD20 
(2H7 APC-H7), CD27 (M-T271 V450), CD3 (PE-Cy5), CD38 (AT-1; Stem Technologies). 
Some experiments used CD95 (DX-2 APC) or CD21 (B-ly4 PE-Cy5) (all from BD Science 
except CD38). Before the cells were stained for extracellular targets, they were incubated with 
LIVE/DEAD (Invitrogen), which is an amine-reactive fluorescent dye that stains dead and dying 
cells positive. All samples were run on an LSRII flow cytometer (BD Biosciences) and the data 
was analyzed using Flowjo software (Tree Star).  
Detection of infected monocytes 48 hrs post stimulation by cytometry 
The detection of infected monocytes occurred after the PBMCs were exposed as 
described above to DENV-2 or DENV-3 before culturing for 48 hours. The cells were collected 
and MACs Buffer was added to the wells. Each well was washed vigorously until all adherent 
cells were removed from the plate. Then the cells were incubated with LIVE/DEAD (Invitrogen) 
as described above; the Ab panel from BD Science used was CD19 (PE-Cy7), CD14 (PB), CD3 
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(PE-Cy5), HLA-DR (FITC) and CD11c (PE). Intracellular staining for virus followed the surface 
staining of the cells. The cells were fixed and permeabilized using Cytofix/Cytoperm kit (BD 
Biosciences), followed by staining with a Alex647 conjugated 2H2 antibody. The 2H2 is an 
IgG2a isotype antibody produced in lab using a hybridoma from a mouse immunized against all 4 
dengue serotypes. Therefore, this is a pan-dengue antibody that recognized the prM protein. An 
Alexa674 anti-mouse IgG2a (Invitrogen) was used to label this antibody following the 
manufacturer’s protocol. Following the intracellular staining, the samples were run on an LSRII 
flow cytometer and analyzed using Flowjo as previously described.  
Growth/ultracentrifugation of DENV prototypes 16681 DENV-2 and H87 DENV-3 
The DENV prototypes used in this study were DENV-2 (16681) and DENV-3 (H87). 
They were propagated on C6/36 cells. At day zero 1x106 cells were infected with an MOI 0.01 of 
virus for 2 hours before the virus was washed off. Then the cells were cultured for 15 days in 
DMEM, 2% FBS, 1% Pen/Strep and 1% phosphotase Broth. Supernatants were collected and 
stored at -80oC at days 5, 7, 9, and 15 dependent on the amount of CPE observed. Then the 
supernatants were pooled and concentrated by centrifugation at 100,000 x g for 4 hours over a 
20% glycerol cushion.  
DENV specific ELISPOT Assay 
The ELISPOT assay used was previously published [67]. To give a brief summary, 96 
well ELISPOT plates were coated with goat anti-human IgG (10 ug/mL; Bethyl Laboratories), 
UV-inactivated DENV-2 (16681) or DENV-3 (H87) that were grown on C6/36 cells and 
concentrated as described above to detect IgG secreting plasmablasts or DENV specific 
plasmablasts, respectively. The concentration of virus used per well was 1x105 PFU/mL and the 
control used was a 2% BSA and IgG coated well with a media only culture. The plates were 
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coated overnight at 4oC. Before adding the stimulated cells- either CpG cocktail or DENV which 
had been stimulated for 7 days- the plates were blocked with RPMI 1640 with 10% FBS for 2 
hours. The desired concentration of cells was then added to each well. After an18-20 hour 
incubation at 37oC, the cells were discarded and washed before a 1 hr incubation with 
biotinylated goat anti-human IgG-Fc (Bethyl Laboratories) at room temperature. Then 
Streptavidin-conjugate alkaline phosphatase (Bio-Rad) was added and the plates were developed 
using an alkaline phosphatase conjugate kit (Bio Rad). CTL ImmunoSpot reader and counting 
software was used to count the spots produced (Cellular Technologies).  
Depletion of CD14+ monocytes 
Depletion of CD14+ cells was achieved by using the MACs cell sorting kit (Miltenyi 
Biotech). This kit positively labels CD14+ cells; the depletion was carried out following the 
manufacturer’s protocol and using a LS depletion column.  
CFSE cell Proliferation Kit 
 In order to follow the proliferation of CD19+ in culture for seven days, the Cell TraceTM 
CFSE Cell Proliferation Kit, for flow cytometry by Invitrogen was used. The protocol issued 
with the kit was followed. Briefly, 1 uL of the Cell TraceTM stock solution was used per 1 mL of 
protein-free buffer. 5 uL of Cell TraceTM was used per 5 mL of 0.1% BSA (BSA and PBS) and 
5x106 million PBMCs. The cells were re-suspended in the dye solution and left in the 37oC hot 
water bath for 30 minutes. Then the cells were washed thoroughly and re-suspended in complete 
R-10 media and left in the hot water bath at 37oC for another 10 minutes. After staining the 
PBMCs, they were stimulated with the CpG cocktail, as described above, or cultured in media 
only for 7 days. At day 7, the PBMCs were collected and stained as described above to look at 
CD19+ population.  
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4.0 RESULTS 
4.1 SPECIFIC AIM 1 RESULTS 
AIM 1: Investigate the ability of DENV to stimulate the differentiation of DENV specific 
memory B-cells into plasmablasts. 
4.1.1 Patient and sample characteristics 
For this study, healthy donors were recruited from the local community. From this group 
of local donors, six reported previous infections with DENV and eight had no history of travel to 
dengue endemic areas. To confirm the immune status of these donors, their serum was tested by 
an in-house anti-DENV IgG ELISA. I confirmed that the serum for all six donors with previous 
exposure to DENV was positive for antibodies that could bind to DENV.  Five of the presumed 
naïve donors did not have DENV binding antibodies in their serum. The remaining three donors 
were dropped from the study due to borderline negative results. Of these remaining donors I 
chose three of the confirmed naïve and three of the confirmed immune to include in the study. 
Figure 1 shows the anti-DENV IgG virus-capture ELISA results for these six donors. The 
demographics and clinical histories for each of the donors are described in Table 1. Additionally, 
plaque reduction neutralization assays were performed using the serum samples to confirm the 
DENV serotypes to which the donors reported being previously exposed. The neutralizing 
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antibodies detected were DENV-3, donors P002 and P004, and DENV-1 and DENV-2, donor 
P026 (Table 1). 
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PRNT data kindly provided by Priscila Castanha, MS from Ernesto Marques lab. 
DONOR ID P002 P004 P026 P040 P044 P046 
Age 30s 30s 30s 30s 20s 20s 
Gender M F F F F F 
Type Infection DF Asymptomatic DHF Naïve Naive Naive 
Neutralizing 
Antibodies 
DENV-3 DENV-3 DENV-1 
DENV-2 
- - - 
Year Infected 2003 2003 - - - - 
The dotted line represents the cut-off OD where all readings below the line are negative and all the readings 
above are positive serum samples for DENV antibodies  
Figure 1. Detection of cross-reactive anti-DENV IgG antibodies in donor serum samples. 
Table 1. Demographic and serological characteristics of the donors. 
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4.1.2 Examining the phenotype and kinetics of the plasmablasts produced after DENV 
exposures 
For this study, I defined plasmablasts as the CD19
+
CD20
-
CD38
++
CD27
++
 population
based on previously published classifications [54]. The gating strategy depicted in Figure 2 was 
used throughout the entire study to classify this cell population. 
A kinetics curve was performed to observe when B-cells start differentiating and up-
regulating CD27
++
CD38
++
, as well as down regulating CD20, which is the classic phenotype of
plasmablasts. Vaccine, clinical and in vitro studies observed that this response takes place 
Representative gating strategy for how plasmablasts were defined from DENV immune individual post 
DENV stimulation and pre-stimulation. G-1 gates on the total cells that have the appropriate Forward and 
Side Scatter to indicate they are neither dead cells or debris. G-2 gates on single cells. G-3 gates on live 
cells. G-4 gates on the CD19
+
CD20
-/low
 B-cell population. G-5 gates on the CD38
++
CD27
++
 plasmablast 
population. 
Figure 2. Gating strategy to define plasmablasts. 
28 
between five to ten days post exposure and peaks at six to seven days [65, 67, 70, 71]. Therefore 
I took samples from day three until day nine, two days before the presumed beginning stages of 
the plasmablast development and two days after the estimated peak, respectively.  PBMCs from 
P026, a DENV immune donor, were used to define this curve, as it was expected that DENV 
would drive a defined plasmablast population (Figure 3A). P040 was used as the negative control 
for a response to DENV without any specific B-cells (Figure 3B). Since memory B-cells have 
high affinity BCR against their specific antigen, they are more sensitive and require less 
activation signals compared to a naïve B-cell; therefore, they rapidly differentiate into 
plasmablasts after antigen exposure in vivo [54]. To ensure that donors with DENV specific 
memory B-cells did not produce a peak plasmablast response before donors without DENV 
specific memory B-cells, I tested donors from both groups. Due to naïve B-cells requiring strong 
activation signals, I speculated that non-specifically activated cells may peak after the reactivated 
memory B-cells population. The amount of plasmablasts in both donors increased gradually each 
day during the nine day kinetics study. This suggests that after DENV stimulation in vitro, the 
plasmablast response uniformly developed in each donor regardless of immune status; however, 
as expected, the overall frequency of the plasmablasts was greater when the donor had DENV 
specific memory B-cells. Based on this curve, day seven was chosen as the time point to look for 
the plasmablasts in the subsequent studies (Figure 3A). Despite the higher percentage of 
plasmablasts at day nine, day seven was chosen because of the difficulty of culturing fragile 
primary B-cells for long periods. 
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(A) Kinetics curve for P026 a DENV immune donor. (B) Kinetics curve for P040 a DENV naïve donor 
Figure 3. Kinetics curve for plasmablast differentiation in culture. 
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4.1.3 Generation of plasmablasts by DENV-induced stimulation 
After establishing that day seven was the optimal day to look for plasmablasts, I 
compared how selected DENV immune and naïve donors responded in culture. Our hypothesis 
was that donors with DENV immunity would produce a strong plasmablast response in culture as 
seen in influenza vaccine studies or clinical dengue infections. As a positive control virus for 
antigen derived plasmablasts in culture, influenza virus was chosen. In the United States (US), 
the Centers for Disease Control of Prevention (CDC) estimates that 38.8 percent of adults 
received the influenza vaccine 2011-2012 [72], so many US adults have a well-maintained 
population of influenza virus specific memory B-cells. The six donors chosen for this set of 
experiments all mounted a high frequency plasmablast response after in vitro stimulation. A 
carboxyfluorescein succinimidyl ester (CFSE) study was also completed to show that B-cells 
could be driven to proliferate in culture. Figure 4A shows the CD19
+
 cells seven days after being
cultured in media only or a strong CpG mitogen cocktail. As shown by the large number of cells 
that had a distinct reduction in florescence, the majority of the CD19
+
 were induced to
proliferate. In contrast, the media only control population mainly stayed a uniformed high 
florescent population indicating they did not undergo proliferation during the seven days. 
It was expected that both DENV naïve and DENV immune donors would have strong 
plasmablast responses in culture to influenza while only the DENV immune donors would 
produce a distinct plasmablast response to DENV (Figure 4B). However, based on multiple 
experiments, only one DENV immune donor produced a defined, but varied, plasmablast 
response in culture.  The three naïve donors produced a low-level plasmablast response.  The two 
remaining DENV immune donors produced a very low plasmablast response in culture. Figure 
4C shows the range of plasmablast responses observed in each donor throughout the study. The 
31 
specificity of these plasmablasts produced as a result of DENV stimulation could not be detected 
by flow cytometry. Based on the low levels of plasmablasts observed in the naïve donor samples, 
DENV is likely able to cause some level of non-specific activation. Another experimental 
approach was taken to determine the specificity of these plasmablasts, as well as whether or not 
this suggests DENV can drive reactivation and proliferation in the DENV specific memory B-
cell population. 
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(A) CFSE study. Both dot-plots represent the CD19
+
 population of the total PBMCs cultured. The left dot-
plot represents the media only control showing very little proliferation while the right dot-plot shows high 
levels of proliferation in the CpG cocktail treated PBMCs. (B) Representative dot-plots of the plasmablast 
response hypothesized to be observe. (C) Range of plasmablast responses observed in each donor 
throughout the study 
Figure 4. Generation of plasmablasts in culture. 
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4.1.4 Specificity of plasmablasts in DENV patients 
The flow cytometry method used in the previous experiments could only measure the 
overall frequency of the plasmablasts produced by the different donors in culture. A system to 
detect the specificity of these plasmablasts by flow cytometry was not available. Therefore an in- 
house ELISPOT assay was used to determine the specificity of the DENV activated 
plasmablasts. A previous study showed that ~70 percent of IgG
+
 secreting plasmablasts obtained
from a dengue patient were specific for DENV-3 [67]. Since this patient was already 
characterized, I used them as a positive control for the assay. Figure 5 shows that the assay was 
working accurately since ~70 percent of the total IgG secreting plasmablasts were specific for 
DENV-3. 
10,000 PBMCs were plated per well. Patient 570 was a previous characterized patient sample with >70% of their 
plasmablasts specific for DENV-3 
Figure 5 Highly DENV specific plasmablast response in patient 570.  
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4.1.5 Frequency of long-lived DENV specific memory B-cells 
Before looking for DENV specific IgG
+
 plasmablasts after stimulating PBMCs from
immune individuals with DENV, tests were designed using a strong mitogen cocktail to make 
sure there was a detectable population of DENV specific IgG
+
 memory B cells in the peripheral
blood. Most investigators searching for class switched memory B cells use a strong mitogen 
when measuring their frequency. The class switch population has been reported to be 250 to 300 
cells/1x10
6
 PBMCs with the percentage of antigen specific B-cells reported to be ~0.01 to 0.1
percent of this class switched population depending on the study and antigen [65, 66, 73]. In 
order to characterize the frequency of DENV specific memory B cells in each DENV immune 
donor, I stimulated PBMCs for seven days using a strong B-cell mitogen cocktail (see methods) 
to drive CD27
+
 memory B-cells to differentiate into antibody secreting cells. I then transferred
the cells in an ELISPOT plate pre-coated with DENV and incubated for twenty hours to capture 
any IgG or DENV specific antibodies (Figure 6A). All 3 DENV immune donors had quite a 
large DENV specific IgG
+
 memory B-cell population relative to the observations referenced
above. Over 0.7 percent of the circulating IgG
+
 memory B-cells in the immune donors were
DENV specific. Two of these donors had over 2 percent of their circulating memory B-cells 
specific for one or two dengue serotypes (Figure 6B).  A donor with no pre-exiting immunity to 
DENV was also stimulated with the same strong mitogen cocktail for seven days and, as 
expected, no DENV IgG
+
 secreting plasmablasts were detected (Figure 6A). These results
suggest that the DENV immune donors have a large DENV specific IgG
+
 long-term memory B-
cell population in their peripheral blood that could be detected by ELISPOT. Since antigen 
stimulation is much weaker compared to a strong mitogen cocktail, if DENV specific antibodies 
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are undetectable by ELISPOT after seven days, this is not related to an absence of DENV 
specific memory B-cells.  
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(A) Representative ELISPOT wells of DENV immune and naïve donors after stimulation with DENV for 7 
days and remaining un-stimulated in culture. This assay detected the plasmablasts secreting Ab reactive 
against IgG, DENV-2, DENV-3 and BSA. (B) Pie charts representing the frequency of DENV specific IgG 
plasmablasts per total IgG plasmablasts.  
Figure 6. Frequency of DENV specific memory B-cells. 
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4.1.6 Specificity of plasmablasts generation after stimulating with DENV-2 
Testing was conducted to determine if DENV alone is a strong enough stimulus to 
specifically reactivate the circulating DENV specific IgG
+
 memory B cells to proliferate and
differentiate into DENV specific IgG secreting plasmablasts. After stimulating the PBMCs with 
DENV-2, I plated a range of cells, 1x10
5 
 to 32,500 cells, in each ELISPOT well and incubated
for twenty hours to capture any DENV specific antibodies secreted by the ASCs. The DENV 
naïve donor used as a negative control produced a low level IgG
+
 response, supporting the initial
observation that the plasmablasts produced in culture were non-specific. In the media only 
controls, there was also a low level of IgG
+
 plasmablasts after seven days (Figure 7A). As shown
in Figure 7B, in two of the donors with a known history of DENV infection, only 2 to 5 percent 
of their ASCs were specific for DENV. The third donor with DENV immunity had undetectable 
levels of DENV specific IgG secreting cells. It is possible their response was so low because I 
needed to plate a higher number of cells per well. These results show that the plasmablast 
population observed by flow cytometry after seven days in culture does not represent a dominant 
DENV specific population as was expected. Even though the percentages of DENV specific IgG 
secreting cells are lower than expected, they still show that DENV can drive DENV specific 
memory B cells to differentiate. These results suggest that the re-activation of DENV specific 
memory B-cells and the plasmablasts they differentiate into do not predominantly make up the 
potent plasmablast response observed in acute patients. 
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(A) Representative ELISPOT wells of DENV immune and naïve donors after stimulation with DENV for 7 
days and remaining un-stimulated in culture. This assay detected the plasmablasts secreting Ab reactive 
against IgG, DENV-2, DENV-3 and BSA. (B) Pie charts presenting the frequency of DENV specific IgG 
secreting cells per total IgG secreting cells 
Figure 7.  Specificity of the plasmablasts produced after stimulation with DENV-2. 
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4.2 SPECIFIC AIM 2 RESULTS 
AIM 2: Determine the role of monocytes in promoting the in vitro expansion of 
plasmablasts in response to DENV stimulation. 
4.2.1 Gating Strategy to define CD14+ Monocytes
The target monocyte population is defined as CD3
-
CD19
-
CD14
+
.
 
The gating strategy shown in
Figure 8 was used to look for DENV infected monocytes and to confirm that CD14
+ 
monocytes
were depleted from the PBMC samples during the preceding experiments. 
Representative gating for identifying monocytes using an un-stimulated PBMC sample. G-1 gates on the 
total cells that have the appropriate Forward and Side Scatter which show they are neither dead cells nor 
debris. G-2 gates on the single cells. G-3 gates on the live cells. G-4 CD3
-
CD19
-
 population. G-5 gates on 
the CD3
-
CD19
-
CD14
+
 monocyte population. Q2 where the 2H2
+
 CD14
+
 monocytes are found with the 
gating based on a control un-infected PBMC sample.  
Figure 8. Gating strategy to define CD14
+
 monocytes. 
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4.2.2 Detection of DENV infected monocytes using intracellular 2H2 antibodies 
After exposing PBMCs from selected donors to DENV and culturing for forty-eight hours, a 
fluorescently labeled 2H2 pan-dengue antibody against for the prM protein was used to probe for 
the presence of intracellular virus. I detected a distinct population of monocytes, CD3
-
CD19
-
CD14
+
, that were positive for 2H2 (Figure 9A). No other cell types, CD3
+
 or CD19
+
, were
positive for 2H2 after forty-eight hours (data not shown) confirming previously published data 
which states that monocytes are the primary target cells for DENV infection [74, 75]. When 
PBMCs were stimulated with completely UV inactivated DENV, I did not detect a 2H2 positive 
monocyte population above background after 48 hours suggesting that this uptake of DENV is 
related to infection (data not shown). This is in-line with previous literature stating that 
monocytes and not T-cells or B-cells are the targets for infection [76]. 
 After testing all three of our DENV immune donors and one DENV naïve donor for 
2H2
+
 monocytes at forty-eight hours, we found that all donors had similar levels of 2H2
+
CD3
-
CD19
-
CD14
+
 monocytes (Figure 9B).  The frequency of this monocyte population is not a
unique characteristic to DENV immune individuals which suggests that their monocytes are not 
uniquely susceptible to DENV infection. There was also no observable link between the 
frequency of the 2H2
+
 monocytes and the ability of the matched donors to produce a defined
plasmablast response in culture. 
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4.2.3 Plasmablast generation after CD14+ depletion of DENV stimulated PBMCs
To directly measure the role monocytes play in the in vitro differentiation of 
plasmablasts, the CD14
+
 cell population was depleted using magnetic beads before DENV
stimulation. Figure 10A shows that the depletion of the CD3
-
CD19
-
CD14
+ 
monocyte population
from PBMCs was >95 percent efficient. After seven days, there was a 50 percent reduction in the 
CD19
+
CD20
-
CD38
++
CD27
++
 plasmablast population in the CD14
-
 PBMC sample compared to
the PBMC sample (Figure 10B). This suggests that monocytes are not the only cell population 
important for the expansion of plasmablasts in culture, as the production of plasmablast in 
culture was not completely abolished. It is possible other cell types such as T-cells play an 
important role. However, this is difficult to confirm without further supporting evidence as the 
general plasmablast response in culture was very low. 
Previous experimental data using a CD19
+
 purified cell population exposed to DENV did
not produce a robust plasmablast response in culture (data not shown). An attempt to look at the 
(A) Representative dot plots of the un-infected PBMC control sample and the matched donor PBMC sample 48 
hours post exposure to DENV-2. (B) Bar graph showing the percent of monocytes infected after 48 hours using 
PBMCs from 3 DENV immune donors and 1 DENV naïve donor 
Figure 9. Detection of DENV infected monocytes by intracellular 2H2 antibodies 
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role of T-cells by depleting the CD3
+
 population before stimulating with DENV was
inconclusive; however, it was observed that the removal of CD3
+ 
cells dramatically affected the
overall cell viability at day seven (Figure 11). It is known that isolated B-cells have poor 
viability in culture and the viability data suggests that CD3
+
 cells may play an important role in
the long-term survival of CD19
+
 cells, as well as other cell types. Even though the frequency of
infected monocytes does not seem to have a significant role in driving plasmablast production, 
the presence of CD14
+
 cells does play a role in the distinctness of the population. Most likely,
the monocyte population plays an important role in the survival, proliferation and differentiation 
of the B-cell population due to the secretion of cytokines such as IL-6 and IL-10 [77]. 
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(A) Efficiency of depleting the CD14
+
 cells from PBMCs using CD14 magnetic beads. (B) Top row shows 
the plasmablast response after stimulating PBMCs with DENV. The bottom row shows the plasmablast 
response after simulating PBMCs depleted of CD14
+
 cells after DENV stimulation. (C) The percent 
reduction of plasmablasts between the whole PBMC and CD14
+
 depleted PBMC samples.  
Figure 10. Generation of plasmablasts in the absence of CD14
+
 cells. 
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As expected, the CD19
+
 population has poor viability while the whole PBMCs have over 80% viability 
after 7 days in culture. When CD3 is depleted from the PBMCs with viability although better than purified 
B-cells is still poor compared to CD14 depleted and whole PBMCs. 
 
Figure 11. Viability of PBMCs/B-cells after 7 days in culture.  
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5.0  DISCUSSION 
As outlined in the introduction, despite decades of research devoted to unraveling the 
pathogenesis of dengue, the immunological events driving DENV infections are still poorly 
understood. Relative to other intensely studied cell types, very little is known about the role 
plasmablasts play in the overall model of DENV pathogenesis. At the start of this project, it was 
unknown if this robust plasmablast response to DENV originated from the DENV specific 
memory B-cell subset or if it originated from a robust response driven by naïve B-cells. The 
overall goal was to tackle a part of this question by investigating the ability of DENV to drive 
memory B-cells from a previous DENV infection into IgG secreting plasmablasts in vitro, and to 
determine if this process occurs independently of other soluble or cellular factors.  
Differentiation of plasmablasts after DENV stimulation in vitro 
In this study, I first aimed to identify if DENV can drive a general production of 
plasmablasts in healthy donors that reached the robust levels observed in PBMCs isolated from 
acute patients. For this purpose, I isolated PBMCs from donors with pre-existing immunity to 
DENV and examined the neutralizing and binding ability of their serum antibodies to develop a 
profile of their spontaneous DENV specific ASCs. The purpose for this was to indirectly identify 
the potential cross-reactivity and specificity of the resting memory B-cell population present in 
PBMCs. I found that regardless of their neutralizing antibody profile, all donors produced an 
average plasmablast response that was stronger or equivalent when stimulated with DENV-2 
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versus DENV-3 in vitro.  This suggests, for reasons unknown, that DENV-2 is a stronger 
stimulator in vitro, but this could be related to the epidemiological observations which suggest 
that DENV-2 is the more virulent serotype [46, 78]; hence, it is linked to more severe disease 
outcomes. It was interesting to note that donors with neutralizing antibodies to only DENV-3 
produced a similar plasmablast response in vitro when exposed to DENV-2. This indicated that 
in vitro their general plasmablast recall response against the original infecting serotype was no 
better than against a heterotypic serotype.  
When examining the overall potency of the plasmablast response in culture, the responses 
only made up ~1 to ~12 percent of the CD19
+
 peripheral B-cell population, which is very low 
compared to the average 47 percent observed during clinical studies [67, 68]. However, this in 
vitro plasmablast response reached the low levels observed during vaccine studies with influenza 
virus or yellow fever virus vaccine [68]. Although in vitro DENV was not able to recapitulate the 
robust response observed during acute infection, DENV was able to drive a general plasmablast 
response that reached comparable levels seen in other viral infections in some donors. Therefore, 
this data suggests that overall the robust plasmablast response seen in acute patients may not 
completely depend on the reactivation of DENV specific memory B-cells, but may also rely on 
the plasmablast subset produced by the GCs formed in response to the ongoing infection. This 
hypothesis is also supported by the observation that when identifying the specificity of the 
plasmablasts during infection at their peak, they predominately secrete IgG against the current 
infecting serotype [67, 68].  
I also examined the effects DENV had on donors without a DENV specific memory B-
cell subset. According to these results, DENV could stimulate a plasmablast response in these 
donors comparable or greater than the individuals with pre-existing immunity. For reasons that I 
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did not further investigate, I could not decrease the level of this non-specific response to reach 
background or very low levels. However, I did establish that this response was not DENV 
specific. This response had evidence of a slight IgG ASCs response, but I did not test the IgM 
ASC population, which would have indicated if DENV was simply non-specifically activating 
the naïve B-cell population in these donors.   
Stimulation of the quiescent DENV specific memory B-cells 
There have not been many studies looking at DENV-induced activation of long-term 
memory B-cells and how this may drive them to differentiate into plasmablasts. Most 
investigators studying this population examine the Ig secreting cells during acute infections or 
isolate a few DENV specific memory B-cells from previously exposed donors to look at 
individual clones [69, 79, 80]. All these studies concentrate on the cross-reactivity of the 
antibodies secreted by these cells rather than how this circulating population may represent the 
long-term memory B-cell population present during the early stages of infection. It is important 
to work towards identifying the founding subset that drives the eventual potent plasmablast 
response seen four to seven days after infection. The specificity of the peak plasmablast response 
to the infecting serotype suggests that a primary response by naïve B-cells may play a role, but is 
it a skewed or strong cross-reactive memory B-cell population that drives the manifestation of 
this response. 
To look at the frequency and the specificity of the DENV specific memory B-cells 
present in the PBMCs drawn directly from the donors, I first used a strong mitogen to reactivate 
B-cells in general. Then using an ELISPOT assay to detect the presence of ASCs that are DENV 
specific, I identified that all 3 DENV immune donors had higher than expected frequencies of 
DENV-specific memory B-cells, 0.72 to 3.70 percent of the IgG ASCs. A previous study using 
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the exact same mitogen cocktail looked into the frequency of long-lived memory B-cells specific 
for vaccinia virus (VV)WR in individuals who were vaccinated for small pox up to fifty years 
before the study. This study found that ~0.1 percent of the IgG secreting cells were VV-specific 
[73]. In a separate study, another group also identified the same frequency of tetanus-specific 
classed switched, memory B-cells using a different detection system [66]. The donors with 
previous clinical histories of DENV-3 infections produced, not surprisingly, a dominant 
frequency of DENV-3 specific IgG secreting cells. This data suggests that for reasons not yet 
fully investigated, DENV specific memory B-cells in individuals who have not been re-
challenged with DENV for over a decade can maintain higher than average frequencies in 
circulation. In addition to this, the frequency of this population, although cross-reactive in nature, 
is still dominantly specific for the previous infecting serotype. If these individuals were re-
infected with DENV and the heterotypic virus was able to reactivate even a small portion of the 
circulating memory B-cells, then the starting overall percent of re-activated DENV specific B-
cells would be higher compared to the average recall response to another viral infection.  
In order to further examine this population, I took this ELISPOT assay one step forward 
and looked for the frequency of the DENV specific IgG secreting cells after stimulating the same 
DENV immune donors with DENV. This aim was to detect if -as in acute patient samples- >70 
percent of the IgG secreting plasmablasts produced in vitro were also DENV specific. The 
outcome observed was that when these donors were stimulated with DENV-2, only 0 to 5 
percent of the plasmablasts produced in culture were specific for any DENV serotype. Not 
surprisingly, the donor with neutralizing antibodies against DENV-2 -hence previous exposure to 
DENV-2- was able to produce the highest frequency of DENV specific IgG ASCs. 
Unexpectedly, when looking at the frequency of DENV specific IgG ASCs in donors with 
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previous exposures to DENV-3, after their PBMCs were re-exposed to DENV-3, they still failed 
to produce any ASCs that were specific for DENV-3 (data not shown). Their overall DENV-2 
response was also weaker, supporting the previous observation that in culture DENV-3 is the 
weaker stimulator of the two tested serotypes.   
In conclusion, although DENV specific memory B-cells were reactivated by DENV to 
become DENV specific IgG secreting plasmablasts, this interaction alone is not sufficient to 
drive the robust plasmablast response observed in culture. Therefore, future study is needed.  
Such a study would look more closely at whether or not these plasmablasts have a skewed 
cytokine profile that may downstream influence how the naïve B-cells mount a plasmablast 
response in reaction to the infection serotype. This investigation would require a mixture of cell 
culture and animal model work. In cell culture, the phenotype of the plasmablasts produced after 
the memory B-cells differentiations can be examined while the dynamics between the cross-
reactive recall response and the primary response to the heterotypic serotype should be examined 
with animals.  
Monocytes are important in driving the differentiation of plasmablasts 
As described in the introduction, monocytes are the primary targets of DENV infections 
both in vivo and in vitro. As the central cell believed responsible for driving severe disease 
manifestations [81], it is necessary to establish a possible link between the monocyte population 
and the differentiation of plasmablasts. To study this role, I first determined that after exposing 
PBMCs to DENV, monocytes become infected and the monocytes with previous DENV 
exposures were not more susceptible. Regardless of immune status, all donors tested had a 
similar frequency of infected monocytes forty-eight hours post stimulation. Using matched 
experiments, this frequency of infection did not seem to correlate to the ability of these 
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individuals to mount an above or below average plasmablast response. These results suggest that 
the efficiency of infection is not a sufficient factor, which is surprising since the ADE is based on 
the hypothesis that higher viremia, thus, more severe disease, is linked to a higher frequency of 
infected monocytes [48]. Using another approach to test the direct role of monocytes, CD14
+
 
cells were depleted from PBMCs before simulating with DENV. The population without CD14
+
 
had a 50 percent reduction in the amount of plasmablast produced compared to the whole PBMC 
control condition. These results suggest monocytes do play a role in the differentiation of 
plasmablasts in culture, but their removal isn’t sufficient to eliminate the development of 
plasmablasts.  
Recent studies have also found that monocytes are important in the development of 
plasmablasts in vitro. In this study, I only looked for monocytes in general, identifying them by 
CD14
+
, but two groups have produced publications stating that monocytes infected with dengue 
favor a CD14
+
CD16
+
 inflammatory monocyte phenotype [77, 80]. This particular monocyte 
subset in culture secretes important cytokines such as IL-6, BAFF/APRIL and IL-10 which are 
cytokines known to promote activation, survival and proliferation in B-cells [77, 81]. In vitro, 
IL-6 is important for promoting survival. IL-10 is required for B-cells to proliferate; this 
cytokine also enhances the proliferation abilities of B-cells when their BCR is engaged [59]. 
BAFF and APRIL are the classic B-cell survival and differentiation factors [82, 83]. The study 
reference above showed that co-culturing DENV infection monocytes (CD14
+
CD16
+
) with 
purified B-cells drove the proliferation and differentiation of resting B-cells, particularly with the 
help of IL-10 and BAFF [77]. Therefore, in the absence of monocytes, particularly the infected 
monocyte population, these cytokines would not be readily available in culture assisting and 
driving the proliferation of B-cells upon reactivation. Hence the plasmablast population would be 
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lower, yet not abolished, as activation due to antigen-BCR engagements could be strong enough 
to drive differentiation yet not proliferation.  
After observing that monocytes are not the only cell type important for driving the 
differentiation of plasmablasts after DENV stimulation, I ran a small study depleting CD3
+
 cells. 
Although the experiment did not conclusively determine the role CD3
+
 cells play, it is suspected 
that they play an important role in survival and help push the activated memory B-cells to 
differentiate. A review by Nature regarding immunological memory states that both naïve and 
memory B-cells both require cognate T-cell help, but the requirements are lower for a memory 
B-cell [62]. Therefore, it is likely T-cells are required for the regulation of initiating secondary 
responses. In addition, when comparing the overall viability of the cells with and without T-cells, 
it was evident that when CD3 cells were depleted the overall survival rate decreased drastically. 
Activated T-cells are primary producers of IL-2, which is an important survival cytokine for B-
cells, as well as other cell types [84]. IL-2 was also added to the co-culture system described 
above suggesting that T-cell help is important. More testing needs to be completed to definitively 
establish the precise roles of each cell type, but previous research, as well as our own, indicates 
that the CD14 and CD3 cells are required for the production of DENV specific plasmablasts 
[77].   
Overall Conclusions 
 As a whole these observations suggest that the DENV specific memory B-cell population 
is not solely responsible for the robust plasmablast response during acute infections. Most likely, 
the cross-reactive DENV specific memory B-cells reactivated during the early events of infection 
play their role either by the antibodies or cytokines they produce. At the worst, the antibodies 
produced early on during the infection could help drive ADE; at the best, they could provide 
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some protection until the primary response against the heterotypic infection kicks in. Future 
studies need to investigate if there is a link between first response plasmablasts originating from 
the original DENV specific memory B-cell subset and the primary responding B-cells. The 
resulting peak plasmablast response at day four to seven most likely consists of plasmablasts 
from both the secondary and primary immune responses. In addition to this, future studies need 
to investigate more definitively how monocytes influence plasmablasts during infections. In vitro 
studies suggest that the cytokines secreted by these cells during infection play an important role 
[77, 81].  
To further examine these possibilities, the ability to draw blood samples long-term after 
recovery -early in a known secondary infection and at the critical points of peak plasmablast 
production- may help build a more complete profile.  Such a profile could help determine if there 
is a connection between the DENV specific memory B-cell population before infection and the 
resulting plasmablast response. Unfortunately, this proves difficult because most patients do not 
present themselves to hospitals for treatment until the manifestation of symptoms, at which time 
the early events of interest have already taken place. The next best model is an animal model 
where there is a known history, known time of infection and known timeframe of responses. In 
vitro studies can be used in a closed system to parse out the factors that influence the phenotypes 
and the characteristics of the generated plasmablasts. Reconstruction of an environment that 
favors a high percent of DENV specific plasmablasts where either DENV specific memory B-
cells or naïve B-cells with the potential to recognize the virus are exposed to DENV may provide 
clues as to how these cells fit into the overall pathogenesis model of DENV.  
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